Cognitive Impact of Myeloma Treatment: What Do Studies on Chemo Brain Reveal?
Published on March 11, 2019
At a recent town meeting in Atlanta, audience member Mark inquired about the cognitive effects of the multiple myeloma treatment lenalidomide (Revlimid). What do studies on chemo brain reveal? Tune in to hear myeloma expert Dr. Jonathan Kaufman, fromThe Winship Cancer Institute, discuss where research is today on the negative cognitive impact of long-term myeloma treatment.
This town meeting is sponsored by Amgen, Janssen Pharmaceuticals and Adaptive Biotechnologies. It is produced by Patient Power in partnership with Winship Cancer Institute of Emory University.
Featuring
You might also like
Transcript | Cognitive Impact of Myeloma Treatment: What Do Studies on Chemo Brain Reveal?
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That's how you’ll get care that's most appropriate for you.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
Audience Member:
Yes. I'm Mark Davis, and I'm a high-risk smoldering myeloma patient of Dr. Lonial's for 63 months. Take 25 milligrams of lenalidomide (Revlimid). I'm curious as to whether there's any research being done on the cognitive effects of Revlimid and the other drugs used to treat myeloma. In other words, are there any studies like with neuropsychologists to study chemo brain and things of that sort?
Jack Aiello:
So before I ask Dr. Kaufman to answer your question, can you say a little bit about what it means to be high-risk smoldering because that's a different definition than high-risk myeloma?
Dr. Kaufman:
Right. When we talked earlier about high-risk myeloma we were really talking about genetic subsets. And it was briefly mentioned earlier, not all smoldering patients are the same. Some smoldering patients we would predict never develop myeloma, and some smoldering patient s, i.e. those that are high-risk, there are certain high-risk features, are much more likely to develop myeloma. And so those patients that have high-risk smoldering, there have been a lot of studies in myeloma including looking at Revlimid to prevent the development of myeloma.
So getting back to the question, I think that the cognitive impact, the negative cognitive impact of long-term Revlimid use is hugely understudied, and we hear about it all the time, but there's not been a lot of good data available that really understands why it occurs. But I think it's certainly a very good question that needs to be addressed.
Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.
